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Background.Sorafenibisamolecular-targeted therapyusedinpalliativetreatmentofadvancedhepatocellularcarcinomainChildA
patients.Aims. Toaddressthequestionofsorafenibasneoadjuvanttreatment. Methods.Wedescribe thecasesof2patientswhohad
surgery after sorafenib. Results. The patients had a largehepatocellular carcinomain the right liver with venous neoplasticthrombi
(1 in the right portal branch, 1 in the right hepatic vein). After 9 months of sorafenib, reassessment showed that tumours had
decreased insizewithanecroticcomponent.Arighthepatectomywiththrombectomywasperformed, andhistopathologyshowed
35% to 60% necrosis. One patient had a recurrence after 6 months and had another liver resection; they are both recurrence-free
since then. Conclusion. Sorafenib can downstage hepatocellular carcinoma and thus could represent a bridge to surgery. It may
be possible to select patients in good general condition with partial regression of the tumour with sorafenib for a treatment in a
curative intent.
1.Introduction
Hepatocellular carcinoma (HCC) represents one of the
highest causes of cancer-related death. Recent advances have
been made for advanced HCC (extrahepatic spread or major
vascular invasion) with molecular-targeted therapies [1]
such as sorafenib (Nexavar, Bayer), which has been indicated
as a palliative therapy in Child A patients since a beneﬁt in
median survival and time to radiologic progression has been
shown in 2 large international trials [1, 2].
We report here the cases of 2 patients who were treated
with sorafenib with a palliative intent but eventually had a
resection after good clinical and radiological response. This
is,toourknowledge,theﬁrst reportofresectionsurgery after
sorafenib.
2.CaseReports
2.1. Case 1. A 56-year-old man presented with asthenia,
right subscapular pain, weight loss, and malaise with
hypoglycaemia. He had a signiﬁcant history of chronic
alcoholism. The laboratory tests showed normal platelet
count, polycythaemia, prothrombin time of 79%, liver
cytolysis, and cholestasis with total bilirubin of 43µmol/L.
Alpha-foeto-protein (AFP) was 282,500ng/mL, and anti-
HCV antibodies were positive with high virus levels. MRI
(Magnetic Resonance Imaging) showed (Figure 1(a))a
120mm hypervascular tumour of the right liver with a right
portal branch tumoral thrombosis reaching the bifurcation.
There was no sign of extra-abdominal spread. The lesion
had all radiological features of HCC (i.e., hypervascular with
portal phase washout). The middle hepatic vein was free of
invasion.
The HCCwas considered as nonresectable because of the
extension of the portal thrombus and its neoplastic features
[3], and a palliative treatment with sorafenib (800mg per
day, total dose received = 216g) was initiated. Nine months
later, the patient was in a better general condition. Sorafenib
was well tolerated (neither gastrointestinal symptoms nor2 International Journal of Hepatology
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Figure 1: MRI of patient 1. (a) Before treatment. (b) After 9 months of treatment with sorafenib.
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Figure 2: Macroscopic aspect of patient 1’s surgical specimen. Trans-
verse section of the liver after ﬁxation in 4% formaldehyde. The
tumour has several nodules, with a focal capsule (∗), and white
areas corresponding to necrosis (arrows).
Figure 3: Microscopic examination of patient 1’s specimen at ∗10
magniﬁcationafter hemalun eosin safran coloration.Bottom of the
ﬁgure shows the HCC with a pseudoglandular aspect; top shows an
eosinophilicirregular area corresponding to necrosis.
skin rash or hand-foot syndrome). Hemoglobin was nor-
mal; there still were cytolysis and cholestasis; AFP was
15,600ng/mL.
An MRI (Magnetic Resonance Imaging) (Figure 1(b))
and a new CT scan showed a 88mm in diameter tumour
(decrease in size of 27%) with a necrotic component. The
portal thrombus was necrotic as well, and the left portal
branch was still free of invasion. The response was classiﬁed
treatment eﬀect (TE) 3 (partial response) in the RECICL
classiﬁcation [4]. A biopsy in the left lobe found chronic
hepatitis lesions without cirrhosis (METAVIR score A1F1).
A surgical treatment was proposed 1 month after cessation
of sorafenib.
At laparotomy, neither ascitis nor peritoneal carcino-
matosis was seen. Frozen biopsies of hilar adenomegalies
were performed to rule out an extrahepatic spread and
showed no malignant cells. The main tumour was found in
segments VI, VII, and VIII with daughter lesions. The liver
appeared to be ﬁbrous but not cirrhotic. We performed a
right hepatectomy extended to a part of segment IV with
a total of 30minutes pedicular clamping and the use of
hanging manoeuvre.
The macroscopic (Figure 2)a n dm i c r o s c o p i c( Figure 3)
histopathological examination showed an HCC with a
pseudoglandular aspect and necrosis (around 35% of the
tumour). Microvascular emboli were found. There were no
tumour cells on resection margins (<1mm between tumour
and resection limits). The right portal branch thrombus was
totally necrotic. Nontumoural liver was METAVIR A1F3/F4.
The postoperative course was uneventful. One year later,
the patient had a recurrence in the anterior segment IV that
was previously left in place. A partial segmentectomy was
performed, and the patient isin remission 6 monthsafter the
second surgery.
2.2. Case 2. The second case is a 68-year-old male patient
with a Child-Pugh A cirrhosis of alcoholic origin, weaned
for 1 year and with grade 1 oesophageal varices. Pain inInternational Journal of Hepatology 3
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Figure 4: CT scan of patient 2. (a) CT scan before treatment. (b) Reassessment CT scan after 9 months of treatment with sorafenib.
Table 1: Summarize of patients’ characteristics.
Case
Before treatment Sorafenib Reassessment Histology
Size (mm) Thrombus AFP
(ng/mL)
Daily dose
(mg)
Time
(months)
Size
(mm)
AFP
(ng/mL) Thrombus Tumour
1 120∗80 Right portal
branch 282,500 800 9 88∗60 15,600 necrotic 35% necrosis,
thrombus necrotic
2 100 Right hepatic vein 3,500 800 9 75 9 necrotic 60% necrosis,
thrombus necrotic
the right hypochondrial area revealed a 100mm in diameter
HCC taking up the whole right liver with a neoplastic
thrombus of the right hepatic vein (Figure 4(a)). AFP was
3,500ng/mL.Afteramultidisciplinarydiscussion,thepatient
was prescribed sorafenib (800mg per day) with a palliative
intent. No adverse eﬀects were observed. Nine months later,
AFP was 9ng/mL, and a reassessment CT scan (Figure 4(b))
showed a 25% decrease of the tumour (75mm); doppler
ultrasoundshowed thethrombustobenecrotic.Considering
this signiﬁcant response to the sorafenib (TE3 response [3]),
aresectionsurgerywasproposed1monthafterwards. Aright
hepatectomywithextractionofthethrombuswasperformed
after a quick inferior vena cava clamping (to prevent spread
during handling of the tumour). There was no complication
in the postoperative course, and the patient was discharged
at day 7.
A moderately diﬀerentiated hepatocellular carcinoma
(grade III in Edmondson’s classiﬁcation) was found at
histopathology, with a necrotic component at 60% and no
vascular emboli. The right hepatic venous thrombus was
totally necrotic.
The patient shows no recurrence 6 months after his
operation.
3.Discussion
We showed through these 2 cases that sorafenib could make
ad i ﬀerence for patients with advanced HCC and put them
back on track for a curative treatment (Table 1).
Sorafenib is an oral multikinase inhibitor of tumourgrowth
and angiogenesis that inhibits cell surface tyrosine kinase
receptors (such as VEGFR and PDGFR) as well as ﬂt-3
and c-kit and downstreams intracellular serine/threonine
kinases in the ras/raf/MAPK cascade [5]. This targeted
therapy is recommended to Child A patients with advanced
HCC and World Health Organization performance status
equal or inferior to 2 [6]. Additional tolerability data from
Child B patients are still needed before sorafenib can be
recommended to this category of patients.
Histopathological examination of the resected liver in our
2 cases shows 35% and 60% of tumournecrosis,a n dt h er i g h t
portal branch thrombi were totally necrotic. Somecases have
already been reported in urology with the regression of a
neoplastic vena cava thrombus in response to sorafenib [7].
Lately, Kudoand Ueshima reported the clinicalexperience of
the use of sorafenib in Japan since it has been approved in
May 2009 and described 15 complete remissions out of 3,7004 International Journal of Hepatology
patients [8]. We found as well in the literature a few case
reports where sorafenib allowed a good response and a second-
step curative intent treatment. Bathaix et al. [9] recently
reported a case where sorafenib led to a very signiﬁcant
regression (about 90%) of the tumour, allowing treating the
patient secondarily in a curative intent with transarterial
chemoembolisation (TACE) and radiotherapy. Vageﬁ and
Hirose [10] described the case of a patient who has been
downstaged by sorafenib and subsequently radiofrequency
ablation to the Milan criteria and is now on a waiting list
for LT. Nevertheless, in none of these cases a liver resection
has been performed after sorafenib, and necrosis has not
been histologically proved. We demonstrate in our 2 case
reports a correlation betweenclinical improvement,decrease
in tumour size on MRI and CT-scan images, and necrosis
component at histopathology.
However, an accurate evaluation of the eﬀect of sorafenib
and the selection criteria of good responders still need to be
deﬁned. One of the problems is that tumour size can remain
the same or increase even if there is a good response to
the drug, misleading the prescriber. Sorafenib induces early
intralesional necrosis that could be detected with dynamic
imaging with tumour perfusion and contrast diﬀusion [11],
orgadolinium-injected MRI [12]. The RECICLclassiﬁcation
proposed by the Liver Cancer Study Group of Japan [4]a n d
based on the treatment eﬀect on the tumour is useful after
molecular-targeted therapy.
Trials are ongoing to evaluate sorafenib as an adjuvant
treatment, the main one being the STORM study (http://cli-
nicaltrials.gov/ct2/show/NCT00692770). Endpoints of this
phase 3-randomized trial are eﬃcacy and safety of sorafenib
versus placebo in the adjuvant treatment of hepatocellular
carcinoma after potentially curative treatment (surgical rese-
ction or local ablation). Here, patients did not receive any
sorafenib postoperativly, as there still are no recommen-
dations about its use as an adjuvant therapy. The S-TACE
study(http://clinicaltrials.gov/ct2/show/NCT00478374)aims
to evaluate the com-bination of TACE and sorafenib,
and othertrials want toassess thecombinationwithsystemic
chemotherapy (http://clinicaltrials.gov/ct2/show/NCT00808
145, and http://clinicaltrials.gov/ct2/show/NCT00844688).
A current study is aiming to assess the antitumour activity
of neoadjuvant sorafenib in patients with resectable HCC
(http://clinicaltrials.gov/ct2/show/NCT01182272).
To our knowledge, there is no reported case in the
literature about surgery after treatment with sorafenib. We
did not observe more bleeding/adhesion during surgery; and
none of our patients presented complications such as wound
dehiscence or incisional hernia, but it should be taken into
ac c oun tthats oraf en ibisaV EGFR and PDGFRinhibitorand
hence has antiangiogenic properties. The same postoperative
complications related to a defect in wound healing might
occur as with bevacizumab (Avastin); there are currently
no recommendations from Bayer. However, the half-life of
sorafenib is only 24 to 48hours, and a period of 1 week
without sorafenib before surgery should be enough to avoid
sorafenib-related complications if there are any.
This case demonstrates that sorafenib could downstage
HCC and thus represents a bridge to surgery. It might
be possible to select patients in good general condition
with partial regression of the tumour with sorafenib for
a treatment in a curative intent: radiotherapy or radio
frequency ablation, surgery, and liver transplantation. Espe-
cially, Child A patients who have been prescribed sorafenib
in a palliative intent should be carefully reassessed as surgery
(or other curative treatments) might still be feasible. The
evaluationofsorafenib asa neoadjuvant treatment should be
considered and randomized trials to be performed to assess
thisoption.Standardradiologicevaluationshouldbedeﬁned
after treatment with sorafenib.
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